Getting your Trinity Audio player ready...

The Alabama Department of Public Health (ADPH) announced today a person who received the Pfizer BioNTech COVID-19 vaccine Tuesday experienced anaphylaxis (a severe allergic reaction) several minutes after taking the vaccine and while in required post-vaccine observation.

The patient was immediately treated with anaphylaxis protocol at Decatur Morgan Hospital, where the vaccine was administered, according to a release.

At this time, the patient is stable and appears to be recovering. Information received is that the patient had a previous history of anaphylaxis to biologic agents and, following risk assessment, wished to proceed with vaccine. Previous anaphylaxis to biologics is a precaution, not a contraindication, to COVID-19 vaccine.

As required by the emergency use authorization (EUA) the adverse reaction has been documented and reported to the manufacturer, according to a release.

As of Wednesday at 7 a.m., Alabama providers reported 15,286 doses of COVID-10 vaccine had been administered in the state. Nationwide, six persons have been reported to have had anaphylaxis after COVID-19 vaccine.

This is the only notice that ADPH has received of any allergic reactions in Alabama. ADPH extends its wishes for a quick recovery to the patient, family and all involved, officials said in a release.